fda glp-1 enforcement news today Targets Telehealth Compounded Marketing in New Warning Letters GLP-1s in 2026: What Brokers

Composite biomarkers for assessing Duchenne muscular dystrophy: an initial assessment

It is manufactured using a Drug Master File (DMF) that guarantees the quality, safety, stability, and purity of the raw materials

Clinicians often recognize this when reviewing serial samplesthe curve looks shifted, rather than absent

Structure Therapeutics is developing GSBR-1290, an oral small molecule GLP-1 agonist that could potentially address the manufacturing scalability challenges facing peptide-based injectablesthe company has noted its current manufacturing capacity could theoretically supply over 120 million patients [46]